Connecting Markets. Empowering People. Transforming Economies.
NiDCC

Insights

Insights and Intelligence

Home Insights and Intelligence

Intelligence for decisions, partnerships and market expansion.

Economic reporting from around the world, filtered to the sectors and policy areas our members build in — part of the same intelligence stream behind the Global Economic Outlook and NiDCC's market reports.

Onco360 Oncology Pharmacy Is Selected As Participating Specialty Pharmacy In ZENBEXUS Limited Dispense Network By Bristol-Myers Squibb

life_sciences — September 22, 2026, 4:12 AM · www.marketscreener.com

Onco360 Oncology Pharmacy Is Selected As Participating Specialty Pharmacy In ZENBEXUS Limited Dispense Network By Bristol-Myers Squibb

Onco360 Oncology Pharmacy has been chosen by Bristol-Myers Squibb to join the limited dispense network for ZENBEXUS (iberdomide). ZENBEXUS is a treatment for adult patients with multiple myeloma who have undergone at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. The drug is distributed exclusively through the ZENBEXUS Risk Evaluation and Mitigation Strategy (REMS) program.

Explore more
Cigna Healthcare Hong Kong Simplifies Online Health Insurance Journey Enabling Customers to Choose Coverage with Confidence

life_sciences — September 22, 2026, 3:00 AM · pan african visions

Cigna Healthcare Hong Kong Simplifies Online Health Insurance Journey Enabling Customers to Choose Coverage with Confidence

Cigna Healthcare Hong Kong has launched a redesigned online health insurance platform to simplify the process of researching, comparing, applying for, and paying for coverage. This enhancement includes intuitive digital tools, real-time support from Cigna professionals, and flexible application and payment options. The initiative responds to a 38% increase in online application platform visits, aiming to empower customers to confidently choose health insurance plans that meet their individual needs.

Explore more
NC reaches settlement with Abbott over contaminated baby formula that led to 2022 shortage

life_sciences — September 21, 2026, 9:30 PM · WRAL

NC reaches settlement with Abbott over contaminated baby formula that led to 2022 shortage

North Carolina has reached a settlement with Abbott Laboratories concerning the contaminated baby formula that caused a nationwide shortage in 2022. Abbott will pay $384 million to resolve Medicaid fraud allegations, with North Carolina receiving over $216,000. Regulators found that Abbott knowingly sold contaminated formula and failed to report positive bacterial test results to the FDA.

Explore more
Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit - Mon, 09/21/2026 - 17:15

life_sciences — September 21, 2026, 9:16 PM · Helus Pharma

Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit - Mon, 09/21/2026 - 17:15

Helus Pharma announced that its CEO, Michael Halstead, will participate in a fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit virtually on September 23, 2026, at 9:00 a.m. EDT. The company, a clinical-stage pharmaceutical firm, is focused on developing novel serotonergic agonists (NSAs) to address mental health conditions like depression and anxiety. Helus Pharma is currently developing HLP003 (Phase 3 for major depressive disorder) and HLP004 (Phase 2 for generalized anxiety disorder).

Explore more
Becton, Dickinson Names Arthur Hu Chief Information, Digital Officer

life_sciences — September 21, 2026, 9:00 PM · marketscreener.com

Becton, Dickinson Names Arthur Hu Chief Information, Digital Officer

Becton, Dickinson and Company has appointed Arthur Hu as its new Chief Information and Digital Officer. The announcement was made on September 21, 2026. This leadership change is part of broader management adjustments at the company, which has seen other recent appointments and a retirement.

Explore more
GRAL Stock Clocks Best Day In Over 1.5 Years — FDA Papers Lift Galleri Approval Hopes

life_sciences — September 21, 2026, 8:50 PM · Yahoo Finance

GRAL Stock Clocks Best Day In Over 1.5 Years — FDA Papers Lift Galleri Approval Hopes

Shares of GRAIL Inc. (GRAL) surged 34% after the FDA posted briefing papers ahead of a review for its Galleri blood test, raising hopes for approval. The FDA reviewers did not flag major concerns about the test's accuracy or safety, despite still questioning whether it should be labeled an "early detection" test. GRAIL expects the FDA to make a decision by early 2027, and a positive panel outcome could increase the likelihood of approval.

Explore more
Eli Lilly Starts Building Record $6.5B Houston Manufacturing Facility

life_sciences — September 21, 2026, 8:39 PM · Bisnow

Eli Lilly Starts Building Record $6.5B Houston Manufacturing Facility

Eli Lilly and Co. has broken ground on a $6.5 billion biomanufacturing facility in Houston's Generation Park, which will produce the company's new GLP-1 pill and other advanced therapeutics. This investment, the largest active pharmaceutical ingredient project in Texas history, is expected to create over 600 high-wage jobs and includes a $12.5 million partnership with San Jacinto College to develop a skilled workforce. The facility marks Lilly's fifth domestic API production site announced since 2020 as part of its $50 billion effort to reshore medicine production.

Explore more
Grail rallies as FDA staff flags no major concerns for multi-cancer test

life_sciences — September 21, 2026, 7:57 PM · Reuters

Grail rallies as FDA staff flags no major concerns for multi-cancer test

Grail's shares surged after FDA staff reviewers indicated no major concerns regarding the accuracy and safety of its multi-cancer blood test, Galleri. The findings are set to be discussed at an FDA external advisers' meeting, despite previous setbacks for the test in a UK trial. An FDA approval would significantly boost the test's distribution and insurance coverage.

Explore more
NovaBridge Biosciences (NBP) CMO trades newly vested shares

life_sciences — September 21, 2026, 7:48 PM · Stock Titan

NovaBridge Biosciences (NBP) CMO trades newly vested shares

NovaBridge Biosciences' Chief Medical Officer, Dennis Phillip Andrew, exercised 10,302 restricted share units (RSUs) on September 17, 2026, receiving 23,695 Ordinary Shares represented by ADSs. He then sold 8,209 Ordinary Shares on September 18, 2026, at $0.71 per share. The transactions were not made under a Rule 10b5-1 trading plan.

Explore more
Moderna Stock Jumps 10%+. Its MRNA Cancer Vaccine Is Getting Ready for Its Next Big Test.

life_sciences — September 21, 2026, 7:40 PM · Moomoo

Moderna Stock Jumps 10%+. Its MRNA Cancer Vaccine Is Getting Ready for Its Next Big Test.

Moderna's stock surged over 10% after the company announced positive early-stage clinical trial results for its mRNA-based cancer vaccine, mRNA-4157, when combined with Merck's Keytruda. The combination therapy showed significant improvement in recurrence-free survival for melanoma patients. This success is paving the way for a pivotal phase 3 trial, positioning the vaccine as a promising new approach in cancer treatment.

Explore more